The IPO of Jiren Pharmaceutical on the Shanghai Stock Exchange main board has been "terminated", with the sale of over 700 varieties of traditional Chinese medicine granules.

On February 24th, Anhui Jiren Pharmaceutical Co., Ltd. (referred to as Jiren Pharmaceutical) had its IPO review status on the Shanghai Stock Exchange Main Board changed to "terminated". This was because Jiren Pharmaceutical and its sponsors withdrew their application for the IPO. According to the relevant provisions of the "Shanghai Stock Exchange Stock Issuance and Listing Review Rules" Article 63, the Shanghai Stock Exchange terminated the review for its IPO. The prospectus shows that Jiren Pharmaceutical is a high-tech enterprise engaged in the research, production, and sales of modern Chinese medicine. The company has established three major product lines: Chinese patent medicine, Chinese medicinal slices, and Chinese medicine formula granules. In terms of Chinese patent medicine, the company's main products include capsules for dispelling wind and detoxification, anti-inflammatory tablets with indigo naturalis, capsules for constipation relief, and clean tablets for pelvic inflammation, among others. For Chinese medicinal slices, the company has high visibility and influence in the industry, with over 700 varieties of Chinese medicinal slices sold during the reporting period. Regarding Chinese medicine formula granules, the company has developed and sold over 500 types of Chinese medicine formula granules, making it the first pilot research enterprise for Chinese medicine formula granules in Anhui Province and the first enterprise to obtain GMP certification for Chinese medicine formula granules. The funds raised in this offering, after deducting issuance expenses, will be used for the following projects based on their importance: Financially, in 2021, 2022, 2023, and January to June 2024, Jiren Pharmaceutical achieved operating revenues of approximately 805 million, 1.025 billion, 1.134 billion, and 593 million yuan respectively. During the same period, the company achieved net profits of approximately 95.17 million, 157 million, 131 million, and 80.16 million yuan respectively.